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Effects of erythropoiesis-stimulating agents on
overall survival of International Prognostic Scoring
System  Low/Intermediate-1 risk, transfusion-inde-
pendent myelodysplastic syndrome patients: a
cohort study
Clinical guidelines recommend the use of erythropoi-
etin-stimulating agents (ESA) in anemic patients with
lower risk myelodysplastic syndrome  (MDS)1-4 and two
registration trials for ESA have just been completed.5,6
We conducted a retrospective study in MDS patients
selected by the characteristics predictive of ESA
response,7,8 treated in common practice and enrolled in
the Italian network of regional MDS registries
(ClinicalTrials.gov Identifier: NCT02808858) within the
Fondazione Italiana Sindromi Mielodisplastiche (FISM). 
The aims of our study were to assess the impact of
ESA treatment on overall survival9 and on the evolution
of MDS into acute myeloid leukemia (AML)10 and to
explore the influence of hematologic response on overall
survival in the subgroup treated with ESA. We included
patients who had de novo MDS (between 1999-2013),
were aged ≥18 years at diagnosis, had International
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Table 1. Characteristics of patients evaluated in the study.
Non-ESA-treated patients ESA-treated patients All patients P
(N=387) (N=758) (N=1145)
N. % N. % N. %
Gender 0.404
Female 159 41.09 331 43.67 490 42.79
Male 228 58.91 427 56.33 655 57.21
Age at diagnosis (years) 0.001
≤60 44 11.37 45 5.94 89 7.77
60-70 87 22.48 164 21.64 251 21.92
70-80 174 44.96 329 43.40 503 43.93
>80 82 21.19 220 29.02 302 26.38
Hemoglobin (g/dL) <0.001
≤ 8 72 18.6 96 12.66 168 14.67
8-10 134 34.63 446 58.84 580 50.66
10-12 181 46.77 216 28.50 397 34.67
IPSS risk group <0.001
Low 167 43.15 425 56.07 592 51.7
Intermediate-1 220 56.85 333 43.93 553 48.3
Revised IPSS risk group <0.001
Very low 85 21.96 154 20.32 239 20.86
Low 149 38.5 400 52.77 549 47.95
Intermediate 72 18.6 96 12.66 168 14.66
High 24 6.2 26 3.43 50 4.36
Very high 2 0.52 0 0 2 0.2
Not evaluable 55 14.22 82 10.82 137 11.97
Cytogenetics 0.388
Very good 15 3.88 31 4.09 46 4.02
Good 292 75.45 592 78.1 884 77.21
Intermediate 34 8.79 73 9.63 107 9.34
Poor 5 1.29 5 0.66 10 0.87
Very poor 3 0.78 2 0.26 5 0.44
Not recorded 38 9.82 55 7.26 93 8.12
Diagnosis(WHO 2008) <0.001
RA 108 27.91 264 34.83 372 32.49
RARS 23 5.94 91 12.01 114 9.96
RAEB1 92 23.77 80 10.55 172 15.02
Del(5q) 14 3.62 39 5.15 53 4.63
MDS-U 23 5.94 12 1.58 35 3.06
RCMD 127 32.82 272 35.88 399 34.85
Erythropoietin alpha
No 87 11.48
Yes 502 66.23
Not recorded 169 22.3
ESA: erytrhropietin-stimulating agent; IPSS: International Prognostic Scoring System; WHO: World Health Organization; RA: refractory anemia; RARS: RA with ringed
sideroblasts; RAEBI: RA with excess blasts I; MDS-U: myelodysplastic syndrome unclassified; RCMD: refractory cytopenia with multilineage dysplasia.   
Prognostic Scoring System (IPSS)-Low or Intermediate-1
(Int-1) risk disease,11 had a baseline hemoglobin (Hb)
≤12.0 g/dL and who had not been previously treated
with disease-modifying agents (lenalidomide/azaciti-
dine). We excluded patients with a baseline erythropoi-
etin level >500 U/L or who were transfusion-dependent
(>2 red blood cell units/4 weeks) according to Nordic
group scoring.7 
Erythropoietin (alpha in the majority of cases, or beta)
was administered at doses ranging between 30000 -
80000 U/week, according to the physicians’ choice, for
at least 12 weeks. Erythroid improvement (HI-E) was
eva-luated applying International Working Group (IWG)
2006 criteria.12
The distribution of patients’ characteristics was sum-
marized using percentiles, for continuous variables, and
percentages and frequencies for categorical variables.
Overall survival was defined as the time from diagnosis
of MDS to death or to the last follow-up date. We esti-
mated the effect of ESA treatment on overall survival
using a Cox proportional hazard model that included a
pre-defined set of known risk factors for mortality (age,
sex, Hb level, IPSS category, diagnosis and cytogenetics),
and ESA treatment as a time-dependent covariate, in
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Table 2. Crude and adjusted effects of clinical variables and treatment with an erythropoiesis-stimulating agent on overall survival (Cox
model) and on progression to acute myeloid leukemia (Fine and Gray model).
Overall survival  (n=1145, 402 deaths) AML evolution(n=997, 74 AML ) 
Cox model Fine and Gray model 
Crude effect Adjusted effect Crude effect Adjusted effect
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Gender
Female 1 1 1 1 -
Male 1.55 [1.26,1.91] <0.001 1.59 [1.29,1.97] <0.001 0.97 [0.61;1.53] 0.887 0.87 [0.52,1.43] 0.577
Age at diagnosis (years) 1.06 [1.05,1.08] <0.001 1.06 [1.05,1.08] <0.001 1.01 [0.99,1.02] 0.507 1.00 [0.98,1.02] 0.927
≤60 1 1
60-70 1.70 [1.01,2.86] 0.046 1.22 [0.50,2.95] 0.661
70-80 3.16 [1.93,5.15] <0.001 1.38 [0.61,3.12] 0.438
>80 5.72 [3.45,9.48] <0.001 0.96 [0.38,2.41] 0.931
Hemoglobin (g/dL) 0.76 [0.71,0.81] <0.001 0.82 [0.70,0.95] 0.011
Hemoglobin (g/dL)
≤8 1 1 1 1 -
8-10 0.62 [0.48,0.79] <0.001 0.66 [0.51,0.85] 0.002 0.54 [0.30,0.96] 0.036 0.54 [0.30,0.98] 0.043
>10 0.32 [0.24,0.43] <0.001 0.34 [0.25,0.46] 0.000 0.38 [0.20,0.73] 0.004 0.48 [0.25,0.93] 0.029
IPSS risk group
Low 1 1
Intermediate-1 1.99 [1.63,2.42] <0.001 3.01 [1.82,4.99] <0.001
Diagnosis (WHO 2008)
RA 1.00 1 - 1 1 -
RARS 0.88 [0.60,1.30] 0.520 0.77 [0.52,1.14] 0.197 0.91 [0.30,2.80] 0.876 0.84 [0.27,2.58] 0.755
RAEB1 (<10% blasti) 3.66 [2.78,4.81] <0.001 3.18 [2.40,4.21] 0.000 6.45 [3.30,12.62] <0.001 6.74 [3.38,13.44] <0.001
RCMD 1.42 [1.09,1.84] 0.008 1.42 [1.09,1.85] 0.009 1.85 [0.92,3.71] 0.083 1.98 [0.97,4.06] 0.061
Others 1.38 [0.94,2.05] 0.104 1.57 [1.05,2.34] 0.026 2.25 [0.89,5.69] 0.085 2.39 [0.94,6.09] 0.068
Cytogenetics
Very good/good 1 1 [1.00,1.00] - 1 1 [1.00,1.00] -
Intermediate/poor/very poor 1.00 [0.72,1.39] 0.983 1.36 [0.98,1.89] 0.068 1.68 [0.91,3.10] 0.097 1.98 [1.02,3.83] 0.043
Not recorded 1.08 [0.75,1.54] 0.681 1.12 [0.78,1.61] 0.542 0.79 [0.29,2.18] 0.650 0.89 [0.32,2.49] 0.818
Serum erythropoietin ≤ 500 U/L
Yes 1 1
Not recorded 1.04 [0.85,1.26] 0.716 0.77 [0.49,1.22] 0.273
ESA treatment (changes with time)
No 1 1
Yes 0.89 [0.73,1.09] 0.251 0.85 [0.69,1.04] 0.119
ESA treatment within 6 months of diagnosis
No 1 1 .
Yes 1.29 [0.82,2.02] 0.276 1.47 [0.92,2.33] 0.106
IPSS: International Prognostic Scoring System; WHO: World Health Organization; RA: refractory anemia; RARS: RA with ringed sideroblasts; RAEBI: RA with excess blasts I;
RCMD: refractory cytopenia with multilineage dysplasia; ESA: erythropoiesis-stimulating agent. 
order to reduce the immortal time bias (ESA-treated
patients were analyzed in the group not treated with
ESA until they received the first dose of an ESA, and in
the ESA group thereafter). 
The effect of ESA on overall survival was assessed in
subgroups defined by sex, age (≤70,  >70 years), Hb level
at diagnosis (≤ 8, >8-10, >10-12 g/dL), World Health
Organization 2008 diagnosis [refractory anemia (RA),
refractory anemia with ringed sideroblasts (RARS),
del(5q), refractory cytopenia with multilineage dysplasia
(RCMD), MDS-unclassified (MDS-U), refractory anemia
with excess blasts (RAEB-1)] and cytogenetic cate-
gories.13 Interaction tests between ESA and each stratify-
ing variable were used to detect effect modifications. 
In the ESA-treated patients, we estimated the effect of
HI-E on overall survival using a Cox proportional hazard
model including the same potential confounders as in
the previous analysis and HI-E as a time-dependent
covariate, excluding the first 6 months of follow-up
(landmark analysis). The proportional hazard assump-
tion was tested using Schoenfeld residuals.
The cumulative incidence of evolution to AML was
estimated considering death from any cause as a com-
peting event. In order to estimate the effect of ESA treat-
ment (within 6 months of the diagnosis of MDS) on the
risk of developing AML, we used the Fine and Gray
model adjusting for the same set of potential con-
founders as that used for overall survival.
Among 3438 patients in the MDS registries, 1145 sat-
isfied the eligibility criteria, had complete records and
were analyzed (Online Supplementary Figure S1). These
patients’ characteristics are shown in Table 1. Overall,
758 patients (66%) received an ESA, and 82% of them
started treatment within 6 months of diagnosis. IPSS risk
was low in 592 (52%) and intermediate-1 in 553 (48%).
The revised IPSS (IPSS-R) was assessed for 1008
patients.   Nearly 30% of ESA-treated patients were >80
years old, 28.5% had moderate anemia, 56% had low-
risk IPSS, and 47% had RA/RARS. As expected, patients
not treated with ESA were younger, had significantly
higher levels of Hb, and a lower proportion (34%) had
RA/RARS.
The overall survival rates at 12, 24, 36 and 60 months
after diagnosis were 91.8% (95% CI: 89.9-93.3), 80.8%
(95% CI: 78.1-83.1), 71.2% (95% CI: 68.1-74.1) and
57.5% (95% CI: 53.6-61.1), respectively (Figure 1A).
No statistically significant difference in overall survival
at 24 months was detected according to ESA treatment,
although patients receiving ESA had lower hazard ratios
(HR) in both univariate (crude HR=0.89; 95% CI: 0.73-
1.09; P=0.251) and multivariate analyses (adjusted
HR=0.85; 95% CI: 0.69-1.04; P=0.119). 
Irrespective of treatment, male sex, increasing age, and
any diagnosis of MDS other than RA or RARS were asso-
ciated with worse survival. Patients who had IPSS inter-
mediate-1 risk had a significantly worse survival than
IPSS low-risk patients (P<0.001). Generally, patients
with severe anemia at diagnosis (<8 g/dL) had signifi-
cantly shorter survival than those with Hb >8 g/dL, with
hazard ratios of 0.66 (95% CI: 0.51-0.85) and 0.34 (95%
CI: 0.25-0.46) for the 8-10 g/dL and 10.1-12 g/dL Hb cat-
egories, respectively. Cytogenetic subtypes were not
associated with differences in overall survival (Table 2). 
A subgroup analysis was performed according to the
risk factors included in the multivariable Cox model: a
favorable effect of ESA (compared to non-treatment)
was suggested for patients with Hb 8-10 g/dL, and with
a diagnosis of RA, RARS or del(5q) (Online Supplementary
Figure S1). 
Among the 758 patients treated with ESA, 109 did not
have a registered IWG response during follow up, but
maintained treatment. Of the MDS patients classified as
IPSS low risk, 72% had responses, whereas the response
rate was 76.8% in those with IPSS intermediate-1 risk,
76.8% also in patients with very low risk according to
the IPSS-R and 65.6% in those with IPSS-R low risk,
confirming our recent observations.14 The cumulative
incidence of HI-E, defined according to IWG 2006 crite-
ria,12 at 3, 6, 12 and 24 months was 35.45% (95% CI:
15.43-21.39), 38.45% (95% CI: 34.67-42.21), 47.09%
(95% CI: 43.14-50.92) and 60.66% (95% CI: 56.62-
64.44), respectively. Overall, we did not observe a strong
difference in overall survival according to HI-E in ESA-
treated patients (HR=0.96; 95% CI: 0.71-1.28; adjusted
HR=1.01; 95% CI: 0.73-1.38) (Figure 1B). 
The risk of evolution into AML could be analyzed for
1109/1145 patients. Eighty patients developed AML dur-
ing the follow up. The estimated 5-year cumulative risk
of developing AML was 10.4% (95% CI: 8.3-12.8). The
risk of AML was estimated to be higher in the RAEB-1
subgroup (sub-distribution HR=6.74; 95% CI: 3.38-
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Figure 1. Overall survival of patients with IPSS lower-risk myelodysplastic
syndrome. (A) Overall survival of the entire population of lower risk MDS
patients analyzed in the study (n=1145), independently of treatment. Overall
survival rates at 12, 24, 36 and 60 months after diagnosis were 91.8%
(95%CI:89.9-93.3), 80.8 % (95%CI:78.1-83.1), 71.2% (95%CI:68.1-74.1) and
57.5% (95%CI:53.6-61.1), respectively. The 95% confidence interval is repre-
sented by the dashed line in the figure. (B) Overall survival of ESA-treated
patients (n=589) evaluated after 6 months of therapy, in the absence of
hematologic improvement (HI-E; IWG 2006 criteria) (continuous line) or
according to achievement of HI-E (dotted line). Epo: erythropoietin. 
A
B
13.44) and for higher risk cytogenetic categories. Having
Hb values >8 g/dL showed a protective effect. ESA treat-
ment within 6 months after the diagnosis of MDS was
not associated with a risk of AML (sub-distribution
HR=1.47; 95% CI: 0.92-2.33).
In this registry-based study we analyzed a large sam-
ple of exclusively IPSS lower risk anemic MDS patients
with complete clinical records: the majority of MDS
lower risk patients received ESA (66%), and, quite cor-
rectly according to published evidence,8 82% of them
within 6 months of diagnosis.15
Response rates to ESA in this study are consistent with
those in previous publications. We also confirm that
response rates are higher in patients in IPSS-R lower risk
categories.14 In this study there was a suggestion of a
stronger protective effect of ESA for World Health
Organization diagnostic categories with lower percent-
ages of blasts and sole erythroid dysplasia. The overall
survival advantage in ESA-treated patients was observed
for cases with Hb 8-10 g/dL prior to treatment.
However, probably because of limited statistical power,
none of these differences by subgroups reached conven-
tional statistical significance. We could not show a global
overall survival advantage in MDS patients who
responded to ESA, unlike some published studies.8,10,15
Treatment with ESA per se did not have a protective
effect against the evolution of MDS into AML.
Our analysis differs from previous ones in several
aspects. Since this is a retrospective analysis, there are
limitations due to possible additional unidentified
parameters affecting survival. We adopted several meas-
ures to reduce the risk of biased evaluation of the effects
of ESA. We excluded all patients who had received, prior
to the ESA, any other drug, such as lenalidomide or azac-
itidine, which could potentially affect erythroid function,
as well as patients who were transfusion dependent
according to IWG criteria. To adjust the comparisons for
the unbalanced distribution of some confounders, well-
established prognostic factors for MDS were included in
the multivariable models. Since ESA treatment was start-
ed at different times from diagnosis, it was modeled as a
time-varying variable to prevent survival time bias,
which was not taken into account in previously pub-
lished studies. Lastly, when estimating the association of
ESA therapy with the risk of evolution to AML, we used
a multivariable Fine and Gray model to account for mor-
tality as a competing risk. 
Guidelines (slightly differently from the recent
approval) recommend ESA for IPSS lower risk patients
with Hb <10 g/dL and serum erythropoietin <500 U/L
(<200 U/L in the European approval) with no transfusion
requirement.1-4 The data from the Surveillance,
Epidemiology, and End Results showed a frequent lack
of adherence.16 We observed that among a group of 397
patients with Hb >10 g/dL, 216 (54%) were treated with
ESA, in disagreement with guidelines, and quite notably
did not show any advantage with regards to overall sur-
vival.
In conclusion, our study confirms the high response
rates of IPSS  and IPSS-R lower risk MDS patients to ESA
treatment and suggests an improvement in survival in
treated patients with Hb 8-10 g/dL pre-treatment. We
also found a trend for a survival advantage in MDS
patients with isolated erythroid dysplasia
(RA/RARS/del5q). Our observations obtained in a large
cohort of MDS patients should support appropriate,
wise use of ESA in clinical practice. 
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